Systematic review: Coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 1, 2006, Pages 27-33

  Nielsen, O H ^a   Ainsworth, M ^a   Csillag, C ^a   Rask Madsen, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARTHROTEC; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETODOLAC; ETORICOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; IODOLE; LUMIRACOXIB; MELODIC; MELOXICAM; MISOPROSTOL; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PARECOXIB; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; TRAMADOL; UNCLASSIFIED DRUG; VALDECOXIB;

ARTERY DISEASE; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC ARTHRITIS; CLINICAL TRIAL; COST; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG SAFETY; DYSPEPSIA; GASTRIC ULCER BLEEDING; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART ARREST; HEART DEATH; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; LOW BACK PAIN; LUNG EMBOLISM; NAUSEA; OSTEOARTHRITIS; PAIN; PATIENT; PERIPHERAL VEIN; PHYSICIAN; PRIORITY JOURNAL; PUSTULOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; STOMACH PERFORATION; STOMACH ULCER; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; RISK FACTORS;

EID: 33644891098     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02745.x     Document Type: Review

References (31)

1. Warner TD Mitchell JA Cyclooxygenase-3 (COX-3): finding in the gaps toward a COX continuum Proc Natl Acad Sci USA 2002 99 13371 3
2. Blain H Boileau C Lapicque F et al. Limitations of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use Br J Pharmacol 2002 53 255 65
3. Vane JR Bakhle YS Botting RM Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 1998 38 97 120
4. Blower AL Brooks A Fenn GC et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use Aliment Pharmacol Ther 1997 11 283 91
5. Warner TD Giuliano F Vojnovic I et al. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis Proc Natl Acad Sci USA 1999 96 7563 8
6. Hooper L Brown TJ Elliott RA et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review Br Med J 2004 329 948 58
7. Fitzgerald GA COX-2 and beyond: approaches to prostaglandin inhibition in human disease Nat Rev Drug Discov 2003 2 879 90
8. Silverstein FE Faich G Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial, celecoxib long-term arthritis safety study J Am Med Assoc 2000 284 1247 55
9. Solomon SD McMurray JJV Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 2005 352 1071 80
10. Sowers JR White WB Pitt B et al. The effects of cyclooxygenase-2 inhibitors and non-steroidal anti-inflammatory therapy on 24-h blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus Arch Intern Med 2005 165 161 8
11. Edwards JE McQuay HJ Moore RA Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Pain 2004 111 286 96
12. Nussmeier NA Whelton AA Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N Engl J Med 2005 352 1081 91
13. Byerly FL Nelson KC Granko RP Morrell DS Cairns BA Valdecoxib-associated acute generalized exanthematous pustolosis Burns 2005 31 383 7
14. Hunt RH Harper S Watson DJ Yu C et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events Am J Gastroenterol 2003 98 1725 33
15. Pallay RM Seger W Adler JL et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial Scand J Rheumatol 2004 33 257 66
16. Schnitzer TJ Burmester GR Mysler E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial Lancet 2004 364 665 74
17. Farkouh ME Kirshner H Harrington RA Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial Lancet 2004 364 675 84
18. Silverstein FE Graham DY Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial Ann Int Med 1995 123 241 9
19. Hernandez-Diaz S Rodriguez LA Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s Arch Intern Med 2000 160 2093 9
20. Pawlik T Konturek PC Konturek JW et al. Impact of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on gastric ulcerogenesis in experimental animals and in humans Eur J Pharmacol 2002 449 1 15
21. Hawkey CJ Nonsteroidal anti-inflammatory drug gastropathy Gastroenterology 2000 119 521 35
22. Ekstrom P Carling L Wettehus S et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study Scand J Gastroenterol 1996 31 753 8
23. Cullen D Bardhan KD Eisner M et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users Aliment Pharmacol Ther 1998 12 135 40
24. Chan FKL Hung LCT Suen BY et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial Gastroenterology 2004 127 1038 43
25. Raskin JB White RH Jaszewski R et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study Am J Gastroenterol 1996 91 223 7
26. Lee C Straus WL Balshaw R Barlas S Vogel S Schnitzer TJ A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis Arthritis Rheum 2004 51 746 54
27. Rau R Herborn G Benefit and risk of methotrexate treatment in rheumatoid arthritis Clin Exp Rheumatol 2004 22 Suppl. 35 S83 94
28. Bresalier RS Sandler RS Quan H et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial N Engl J Med 2005 352 1092 102
29. Graham DJ Campen D Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study Lancet 2005 365 475 81
30. Johnsen SP Larsson H Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs Arch Intern Med 2005 165 978 84
31. Laine L Bombardier C Hawkey CJ et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis Gastroenterology 2002 123 1006 12